Hainan Hailing Chemipharma Corp. Ltd.

This study aimed to investigate the pharmacokinetic characteristics of faropenem sodium tablets (200 mg) developed and produced by Hainan Hailing Chemical Pharmaceutical Co., Ltd. after single fasting and postprandial oral administration in healthy subjects; Faropenem sodium tablets (Farom®, 200 mg) licensed and produced by Maruho Co., Ltd were used as the reference preparation, and the pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two preparations were compared to evaluate the bioequivalence of the two preparations in humans.

The main purpose of this study is to evaluate the pharmacokinetic differences of Hemay 005 tablets in subjects with mild, moderate renal impairment and normal renal function, and to provide a basis for formulating clinical medication plans for patients with renal impairment.

The main purpose of this study is to evaluate the pharmacokinetic differences of Hemay 005 tablets in subjects with mild and moderate liver impairment and normal liver function, and to provide a basis for formulating clinical medication plans for patients with liver impairment.